porozendoОстеопороз и остеопатииOsteoporosis and Bone Diseases2072-26802311-0716Endocrinology Research Centre10.14341/osteo12929porozendo-12929Research ArticleНаучный обзорReviewОсобенности костного ремоделирования у больных сахарным диабетом: фокус на витамин К2Bone metabolism in diabetes mellitus: focus on vitamin K2https://orcid.org/0000-0003-3224-1573РадугинФ. М.RaduginF. M.

Радугин Федор Михайлович, аспирант кафедры эндокринологии; eLibrary SPIN: 7043-3620

Санкт-Петербург

Fyodor M. Radugin, postgraduate student of the Departmentof Endocrinology; eLibrary SPIN: 7043-3620

Saint-Petersburg

radugin.f.m@gmail.comhttps://orcid.org/0000-0002-1547-0123КароноваТ. Л.KaronovaT. L.

Каронова Татьяна Леонидовна, д.м.н., главный научный сотрудник НИЛ клинической эндокринологии Института эндокринологии, профессор кафедры эндокринологии; eLibrary SPIN: 3337-4071

194021, Санкт-Петербург, пр. Пархоменко, д. 15

Tatiana L. Karonova, MD, PhD, chief researcher of Clinical Endocrinology Laboratory of the Institute of Endocrinology, professor of the Department of Endocrinology; eLibrary SPIN: 3337-4071

194021, Saint-Petersburg, 15 Parkhomenko Avenue

karonova@mail.ruФГБУ «НМИЦ им. В.А. Алмазова» Минздрава РоссииРоссияAlmazov National Medical Research CentreRussian Federation2021150220222431118Copyright © Радугин Ф.М., Каронова Т.Л., 20222022Радугин Ф.М., Каронова Т.Л.Radugin F.M., Karonova T.L.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.osteo-endojournals.ru/jour/article/view/12929

Сахарный диабет (СД) 2 типа является одним из наиболее распространённых заболеваний, как в мире, так и в Российской Федерации, при котором хронические осложнения, развивающиеся в условиях гипергликемии, представляют серьёзную социально-экономическую проблему. Помимо классических осложнений СД, таких как диабетическая ретинопатия, нефропатия и полинейропатия, в последнее время обращает на себя внимание наличие повышенного риска переломов у больных СД 2 типа даже при нормальных показателях минеральной плотности кости, получившее название «диапороз» или «диабетопороз» и рассматривающееся, как еще одно осложнение СД. Известно, что остеопороз так же, как и СД 2 типа, является широко распространённой патологией и встречается чаще у лиц старшей возрастной группы, что делает их сочетание у одного пациента весьма вероятным. Принимая во внимание высокую социальную значимость и инвалидизацию вследствие остеопоротических переломов и хронических осложнений СД 2 типа, становится необходимым продолжение изучения физиологических и биохимических основ формирования и ремоделирования костной ткани, и патогенетических механизмов остеопороза в условиях хронической гипергликемии. Одним из довольно новых факторов, который, по мнению экспертов, может представлять связующее звено между нарушением углеводного обмена и костным ремоделированием является остеокальцин, концентрация которого находится в зависимости от обеспечения витамином К2, который сегодня рассматривается как потенциальный агент для профилактики остеопоротических переломов. В данной обзорной статье будет освещена актуальная информация о влиянии витамина K2 на состояние костной ткани и возможности использования данного нутриента в клинической практике с фокусом на больных СД.

Diabetes mellitus (DM) type 2 is reported to be among the most common diseases both worldwide and in Russian Federation, whereby chronic implications that develop under hyperglycemia pose a serious socioeconomic problem. Besides of classic microvascular complications like diabetic retinopathy, nephropathy and polyneuropathy it’s recently worthy of note the presence of high fracture risk in DM type 2 even in normal bone mass density, known as “diaporosis” or “diabetoporosis” considered as another DM complication. It is well known that osteoporosis is reported to be widespread disease as same as DM type 2 and likewise is a widely abundant in older age that makes their combination is really possible in a single patient. Taking into account high social value and disability due to osteoporotic fractures and chronic DM type 2 complications it becomes necessary to continue physiologic and biochemical basis investigations of bone formation and remodeling and pathogenesis of osteoporosis development in the context of chronic hyperglycemia. One of the fairly new factors which the experts believe it is link between impaired glucose metabolism and bone remodeling is osteocalcin which concentration is dependent on vitamin K2 maintenance considered as a potential agent in osteoporotic fractures prevention. In this review current information on vitamin K2 influence on bone status and possibility of using this nutrient in clinical practice in the focus on patients with DM will be covered.

сахарный диабетвитамин K2костная тканьостеопорозdiabetes mellitusvitamin k2boneosteoporosisReferencesFerland G. The discovery of vitamin K and its clinical applications. Ann Nutr Metab. 2012;61(3):213-218. doi: https://doi.org/10.1159/000343108Ferland G. The discovery of vitamin K and its clinical applications. Ann Nutr Metab. 2012;61(3):213-218. doi: https://doi.org/10.1159/000343108Gundberg CM, Lian JB, Booth SL. Vitamin K-dependent carboxylation of osteocalcin: friend or foe? Adv Nutr. 2012;3(2):149-157. doi: https://doi.org/10.3945/an.112.001834Gundberg CM, Lian JB, Booth SL. Vitamin K-dependent carboxylation of osteocalcin: friend or foe? Adv Nutr. 2012;3(2):149-157. doi: https://doi.org/10.3945/an.112.001834Zurynski Y, Grover CJ, Jalaludin B, Elliott EJ. Vitamin K deficiency bleeding in Australian infants 1993-2017: an Australian Paediatric Surveillance Unit study. Arch Dis Child. 2020;105(5):433-438. doi: https://doi.org/10.1136/archdischild-2018-316424Zurynski Y, Grover CJ, Jalaludin B, Elliott EJ. Vitamin K deficiency bleeding in Australian infants 1993-2017: an Australian Paediatric Surveillance Unit study. Arch Dis Child. 2020;105(5):433-438. doi: https://doi.org/10.1136/archdischild-2018-316424Бельмер С.В. Роль кишечной микрофлоры в обеспечении организма фолиевой кислотой, витаминами B12 и K // Вопросы современной педиатрии. — 2005.— Т. 4. — №5. — С. 74-76.Belmer SV. Rol kishechnoy mikroflory v obespechenii organizma folievoy kislotoy, vitaminami B12 i K. Voprosy sovremennoy pediatrii. 2005;4(5):74-76. (In Russ.).Palermo A, Tuccinardi D, D’Onofrio L, et al. Vitamin K and osteoporosis: Myth or reality? Metabolism. 2017;70:57-71. doi: https://doi.org/10.1016/j.metabol.2017.01.032Palermo A, Tuccinardi D, D’Onofrio L, et al. Vitamin K and osteoporosis: Myth or reality? Metabolism. 2017;70:57-71. doi: https://doi.org/10.1016/j.metabol.2017.01.032Beulens JW, Booth SL, van den Heuvel EG, et al. The role of menaquinones (vitamin K2) in human health. Br J Nutr. 2013;110(8):1357-1368. doi: https://doi.org/10.1017/S0007114513001013Beulens JW, Booth SL, van den Heuvel EG, et al. The role of menaquinones (vitamin K2) in human health. Br J Nutr. 2013;110(8):1357-1368. doi: https://doi.org/10.1017/S0007114513001013Громова О.А., Торшин И.Ю., Гарасько Е.В., и др. Системный анализ взаимосвязей между метаболизмом витаминов микробиотой и выживанием позитивной микрофлоры ЖКТ // Экспериментальная и клиническая гастроэнтерология. — 2013. — №2. — С. 28-36.Gromova OA, Torshin IYu, Garas’ko EV. et al System analysis of the relationship between the metabolism of vitamins by micro-biota and the survival of the positive microflora of the digestive tract. Experimental and clinical gastroenterology. 2013;2:28-36 (In Russ.).Li J, Zhang H, Yang C, Li Y, Dai Z. An overview of osteocalcin progress. J Bone Miner Metab. 2016;34(4):367-379. doi: https://doi.org/10.1007/s00774-015-0734-7Li J, Zhang H, Yang C, Li Y, Dai Z. An overview of osteocalcin progress. J Bone Miner Metab. 2016;34(4):367-379. doi: https://doi.org/10.1007/s00774-015-0734-7Mizokami A, Kawakubo-Yasukochi T, Hirata M. Osteocalcin and its endocrine functions. Biochem Pharmacol. 2017;132:1-8. doi: https://doi.org/10.1016/j.bcp.2017.02.001Mizokami A, Kawakubo-Yasukochi T, Hirata M. Osteocalcin and its endocrine functions. Biochem Pharmacol. 2017;132:1-8. doi: https://doi.org/10.1016/j.bcp.2017.02.001Панкратова Ю.В., Пигарова Е.А., Дзеранова Л.К. Витамин К-зависимые белки: остеокальцин, матриксный Gla-белок и их внекостные эффекты // Ожирение и метаболизм. — 2013. — Т. 10. — №2. — С. 11-18.Pankratova YuВ, Pigarova EA, Dzeranova LK. Vitamin K-dependent proteins: osteocalcin, matrix Gla-protein and extra osseous effects. Obesity and metabolism. 2013;10(2):11-18. (In Russ.). doi: https://doi.org/10.14341/2071-8713-4818Khaw K-T, Stewart AW, Waayer D, et al. Effect of monthly high-dose vitamin D supplementation on falls and nonvertebral fractures: secondary and post-hoc outcomes from the randomised, double-blind, placebo-controlled ViDA trial. Lancet Diabetes Endocrinol. 2017;5(6):438-447. doi: https://doi.org/10.1016/S2213-8587(17)30103-1Khaw K-T, Stewart AW, Waayer D, et al. Effect of monthly high-dose vitamin D supplementation on falls and nonvertebral fractures: secondary and post-hoc outcomes from the randomised, double-blind, placebo-controlled ViDA trial. Lancet Diabetes Endocrinol. 2017;5(6):438-447. doi: https://doi.org/10.1016/S2213-8587(17)30103-1Urayama S, Kawakami A, Nakashima T, et al. Effect of vitamin K2 on osteoblast apoptosis: Vitamin K2 inhibits apoptotic cell death of human osteoblasts induced by Fas, proteasome inhibitor, etoposide, and staurosporine. J Lab Clin Med. 2000;136(3):181-193. doi: https://doi.org/10.1067/mlc.2000.108754Urayama S, Kawakami A, Nakashima T, et al. Effect of vitamin K2 on osteoblast apoptosis: Vitamin K2 inhibits apoptotic cell death of human osteoblasts induced by Fas, proteasome inhibitor, etoposide, and staurosporine. J Lab Clin Med. 2000;136(3):181-193. doi: https://doi.org/10.1067/mlc.2000.108754Kameda T, Miyazawa K, Mori Y, et al. Vitamin K2 inhibits osteoclastic bone resorption by inducing osteoclast apoptosis. Biochem Biophys Res Commun. 1996;220(3):515-519. doi: https://doi.org/10.1006/bbrc.1996.0436Kameda T, Miyazawa K, Mori Y, et al. Vitamin K2 inhibits osteoclastic bone resorption by inducing osteoclast apoptosis. Biochem Biophys Res Commun. 1996;220(3):515-519. doi: https://doi.org/10.1006/bbrc.1996.0436Koshihara Y, Hoshi K, Okawara R, et al. Vitamin K stimulates osteoblastogenesis and inhibits osteoclastogenesis in human bone marrow cell culture. J Endocrinol. 2003;176(3):339-348. doi: https://doi.org/10.1677/joe.0.1760339Koshihara Y, Hoshi K, Okawara R, et al. Vitamin K stimulates osteoblastogenesis and inhibits osteoclastogenesis in human bone marrow cell culture. J Endocrinol. 2003;176(3):339-348. doi: https://doi.org/10.1677/joe.0.1760339Ohsaki Y, Shirakawa H, Miura A, et al. Vitamin K suppresses the lipopolysaccharide-induced expression of inflammatory cytokines in cultured macrophage-like cells via the inhibition of the activation of nuclear factor κB through the repression of IKKα/β phosphorylation. J Nutr Biochem. 2010;21(11):1120-1126. doi: https://doi.org/10.1016/j.jnutbio.2009.09.011Ohsaki Y, Shirakawa H, Miura A, et al. Vitamin K suppresses the lipopolysaccharide-induced expression of inflammatory cytokines in cultured macrophage-like cells via the inhibition of the activation of nuclear factor κB through the repression of IKKα/β phosphorylation. J Nutr Biochem. 2010;21(11):1120-1126. doi: https://doi.org/10.1016/j.jnutbio.2009.09.011Reddi K, Henderson B, Meghji S, et al. Interleukin 6 production by lipopolysaccharide-stimulated human fibroblasts is potently inhibited by naphthoquinone (vitamin K) compounds. Cytokine. 1995;7(3):287-290. doi: https://doi.org/10.1006/cyto.1995.0034Reddi K, Henderson B, Meghji S, et al. Interleukin 6 production by lipopolysaccharide-stimulated human fibroblasts is potently inhibited by naphthoquinone (vitamin K) compounds. Cytokine. 1995;7(3):287-290. doi: https://doi.org/10.1006/cyto.1995.0034Schröder M, Riksen EA, He J, et al. Vitamin K2 Modulates Vitamin D-Induced Mechanical Properties of Human 3D Bone Spheroids In Vitro. JBMR Plus. 2020;4(9):e10394. doi: https://doi.org/10.1002/jbm4.10394Schröder M, Riksen EA, He J, et al. Vitamin K2 Modulates Vitamin D-Induced Mechanical Properties of Human 3D Bone Spheroids In Vitro. JBMR Plus. 2020;4(9):e10394. doi: https://doi.org/10.1002/jbm4.10394Weng SJ, Yan DY, Gu LJ, et al. Combined treatment with vitamin K2 and PTH enhanced bone formation in ovariectomized rats and increased differentiation of osteoblast in vitro. Chem Biol Interact. 2019;300:101-110. doi: https://doi.org/10.1016/j.cbi.2019.01.012Weng SJ, Yan DY, Gu LJ, et al. Combined treatment with vitamin K2 and PTH enhanced bone formation in ovariectomized rats and increased differentiation of osteoblast in vitro. Chem Biol Interact. 2019;300:101-110. doi: https://doi.org/10.1016/j.cbi.2019.01.012Li H, Zhou Q, Bai BL, et al. Effects of combined human parathyroid hormone (1-34) and menaquinone-4 treatment on the interface of hydroxyapatite-coated titanium implants in the femur of osteoporotic rats. J Bone Miner Metab. 2018;36(6):691-699. doi: https://doi.org/10.1007/s00774-017-0893-9Li H, Zhou Q, Bai BL, et al. Effects of combined human parathyroid hormone (1-34) and menaquinone-4 treatment on the interface of hydroxyapatite-coated titanium implants in the femur of osteoporotic rats. J Bone Miner Metab. 2018;36(6):691-699. doi: https://doi.org/10.1007/s00774-017-0893-9Iwamoto J, Yeh JK, Takeda T. Effect of vitamin K2 on cortical and cancellous bones in orchidectomized and/or sciatic neurectomized rats. J Bone Miner Res. 2003;18(4):776-783. doi: https://doi.org/10.1359/jbmr.2003.18.4.776Iwamoto J, Yeh JK, Takeda T. Effect of vitamin K2 on cortical and cancellous bones in orchidectomized and/or sciatic neurectomized rats. J Bone Miner Res. 2003;18(4):776-783. doi: https://doi.org/10.1359/jbmr.2003.18.4.776Iwamoto J, Matsumoto H, Tadeda T, et al. Comparison of the effect of vitamin K(2) and risedronate on trabecular bone in glucocorticoidtreated rats: a bone histomorphometry study [retracted in: Yonsei Med J. 2018;59(1):168]. Yonsei Med J. 2009;50(2):189-194. doi: https://doi.org/10.3349/ymj.2009.50.2.189Iwamoto J, Matsumoto H, Tadeda T, et al. Comparison of the effect of vitamin K(2) and risedronate on trabecular bone in glucocorticoidtreated rats: a bone histomorphometry study [retracted in: Yonsei Med J. 2018;59(1):168]. Yonsei Med J. 2009;50(2):189-194. doi: https://doi.org/10.3349/ymj.2009.50.2.189Iwamoto J, Matsumoto H, Takeda T, et al. Effects of vitamin K2 on cortical and cancellous bone mass, cortical osteocyte and lacunar system, and porosity in sciatic neurectomized rats. Calcif Tissue Int. 2010;87(3):254-262. doi: https://doi.org/10.1007/s00223-010-9387-7Iwamoto J, Matsumoto H, Takeda T, et al. Effects of vitamin K2 on cortical and cancellous bone mass, cortical osteocyte and lacunar system, and porosity in sciatic neurectomized rats. Calcif Tissue Int. 2010;87(3):254-262. doi: https://doi.org/10.1007/s00223-010-9387-7Kobayashi M, Hara K, Akiyama Y. Effect of menatetrenone (V.K2) on bone mineral density and bone strength in Ca/Mg deficient rats. Nihon Yakurigaku Zasshi. 2002;120(3):195-204. doi: https://doi.org/10.1254/fpj.120.195Kobayashi M, Hara K, Akiyama Y. Effect of menatetrenone (V.K2) on bone mineral density and bone strength in Ca/Mg deficient rats. Nihon Yakurigaku Zasshi. 2002;120(3):195-204. doi: https://doi.org/10.1254/fpj.120.195Boulier A, Schwarz J, Lespesailles E, et al. Combination of micellar casein with calcium and vitamins D2 and K2 improves bone status of ovariectomized mice. Osteoporos Int. 2016;27(10):3103-3112. doi: https://doi.org/10.1007/s00198-016-3638-zBoulier A, Schwarz J, Lespesailles E, et al. Combination of micellar casein with calcium and vitamins D2 and K2 improves bone status of ovariectomized mice. Osteoporos Int. 2016;27(10):3103-3112. doi: https://doi.org/10.1007/s00198-016-3638-zGigante A, Torcianti M, Boldrini E, et al. Vitamin K and D association stimulates in vitro osteoblast differentiation of fracture site derived human mesenchymal stem cells. J Biol Regul Homeost Agents. 2008;22(1):35-44.Gigante A, Torcianti M, Boldrini E, et al. Vitamin K and D association stimulates in vitro osteoblast differentiation of fracture site derived human mesenchymal stem cells. J Biol Regul Homeost Agents. 2008;22(1):35-44.Sasaki H, Miyakoshi N, Kasukawa Y, et al. Effects of combination treatment with alendronate and vitamin K(2) on bone mineral density and strength in ovariectomized mice. J Bone Miner Metab. 2010;28(4):403-409. doi: https://doi.org/10.1007/s00774-009-0148-5Sasaki H, Miyakoshi N, Kasukawa Y, et al. Effects of combination treatment with alendronate and vitamin K(2) on bone mineral density and strength in ovariectomized mice. J Bone Miner Metab. 2010;28(4):403-409. doi: https://doi.org/10.1007/s00774-009-0148-5Fu X, Moreines J, Booth SL. Vitamin K supplementation does not prevent bone loss in ovariectomized Norway rats. Nutr Metab (Lond). 2012;9(1):12. doi: https://doi.org/10.1186/1743-7075-9-12Fu X, Moreines J, Booth SL. Vitamin K supplementation does not prevent bone loss in ovariectomized Norway rats. Nutr Metab (Lond). 2012;9(1):12. doi: https://doi.org/10.1186/1743-7075-9-12Kaneki M, Hodges SJ, Hosoi T, et al. Japanese fermented soybean food as the major determinant of the large geographic difference in circulating levels of vitamin K2: possible implications for hip-fracture risk [published correction appears in Nutrition. 2006;22(10):1075. Hedges SJ [corrected to Hodges SJ]]. Nutrition. 2001;17(4):315-321. doi:10.1016/s0899-9007(00)00554-2Kaneki M, Hodges SJ, Hosoi T, et al. Japanese fermented soybean food as the major determinant of the large geographic difference in circulating levels of vitamin K2: possible implications for hip-fracture risk [published correction appears in Nutrition. 2006;22(10):1075. Hedges SJ [corrected to Hodges SJ]]. Nutrition. 2001;17(4):315-321. doi:10.1016/s0899-9007(00)00554-2Iwamoto J. Vitamin K2 therapy for postmenopausal osteoporosis. Nutrients. 2014;6(5):1971-1980. doi: https://doi.org/10.3390/nu6051971Iwamoto J. Vitamin K2 therapy for postmenopausal osteoporosis. Nutrients. 2014;6(5):1971-1980. doi: https://doi.org/10.3390/nu6051971Horiuchi T, Kazama H, Araki A, et al. Impaired gamma carboxylation of osteocalcin in elderly women with type II diabetes mellitus: relationship between increase in undercarboxylated osteocalcin levels and low bone mineral density. J Bone Miner Metab. 2004;22(3):236-240. doi: https://doi.org/10.1007/s00774-003-0473-zHoriuchi T, Kazama H, Araki A, et al. Impaired gamma carboxylation of osteocalcin in elderly women with type II diabetes mellitus: relationship between increase in undercarboxylated osteocalcin levels and low bone mineral density. J Bone Miner Metab. 2004;22(3):236-240. doi: https://doi.org/10.1007/s00774-003-0473-zKnapen MH, Schurgers LJ, Vermeer C. Vitamin K2 supplementation improves hip bone geometry and bone strength indices in postmenopausal women. Osteoporos Int. 2007;18(7):963-972. doi: https://doi.org/10.1007/s00198-007-0337-9Knapen MH, Schurgers LJ, Vermeer C. Vitamin K2 supplementation improves hip bone geometry and bone strength indices in postmenopausal women. Osteoporos Int. 2007;18(7):963-972. doi: https://doi.org/10.1007/s00198-007-0337-9Knapen MH, Drummen NE, Smit E, et al. Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. Osteoporos Int. 2013;24(9):2499-2507. doi: https://doi.org/10.1007/s00198-013-2325-6Knapen MH, Drummen NE, Smit E, et al. Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. Osteoporos Int. 2013;24(9):2499-2507. doi: https://doi.org/10.1007/s00198-013-2325-6Cockayne S, Adamson J, Lanham-New S, et al. Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials [published correction appears in JAMA Intern Med. 2018;178(6):875-876]. Arch Intern Med. 2006;166(12):1256. doi: https://doi.org/10.1001/archinte.166.12.1256Cockayne S, Adamson J, Lanham-New S, et al. Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials [published correction appears in JAMA Intern Med. 2018;178(6):875-876]. Arch Intern Med. 2006;166(12):1256. doi: https://doi.org/10.1001/archinte.166.12.1256Inoue T, Fujita T, Kishimoto H, et al. Randomized controlled study on the prevention of osteoporotic fractures (OF study): a phase IV clinical study of 15-mg menatetrenone capsules. J Bone Miner Metab. 2009;27(1):66-75. doi: https://doi.org/10.1007/s00774-008-0008-8Inoue T, Fujita T, Kishimoto H, et al. Randomized controlled study on the prevention of osteoporotic fractures (OF study): a phase IV clinical study of 15-mg menatetrenone capsules. J Bone Miner Metab. 2009;27(1):66-75. doi: https://doi.org/10.1007/s00774-008-0008-8Binkley N, Harke J, Krueger D, et al. Vitamin K treatment reduces undercarboxylated osteocalcin but does not alter bone turnover, density, or geometry in healthy postmenopausal North American women. J Bone Miner Res. 2009;24(6):983-991. doi: https://doi.org/10.1359/jbmr.081254Binkley N, Harke J, Krueger D, et al. Vitamin K treatment reduces undercarboxylated osteocalcin but does not alter bone turnover, density, or geometry in healthy postmenopausal North American women. J Bone Miner Res. 2009;24(6):983-991. doi: https://doi.org/10.1359/jbmr.081254Emaus N, Gjesdal CG, Almås B, et al. Vitamin K2 supplementation does not influence bone loss in early menopausal women: a randomised double-blind placebocontrolled trial. Osteoporos Int. 2010;21(10):1731-1740. doi: https://doi.org/10.1007/s00198-009-1126-4Emaus N, Gjesdal CG, Almås B, et al. Vitamin K2 supplementation does not influence bone loss in early menopausal women: a randomised double-blind placebocontrolled trial. Osteoporos Int. 2010;21(10):1731-1740. doi: https://doi.org/10.1007/s00198-009-1126-4Huang ZB, Wan SL, Lu YJ, et al. Does vitamin K2 play a role in the prevention and treatment of osteoporosis for postmenopausal women: a meta-analysis of randomized controlled trials. Osteoporos Int. 2015;26(3):1175-1186. doi:10.1007/s00198-014-2989-6Huang ZB, Wan SL, Lu YJ, et al. Does vitamin K2 play a role in the prevention and treatment of osteoporosis for postmenopausal women: a meta-analysis of randomized controlled trials. Osteoporos Int. 2015;26(3):1175-1186. doi:10.1007/s00198-014-2989-6Tsugawa N, Shiraki M, Suhara Y, et al. Vitamin K status of healthy Japanese women: age-related vitamin K requirement for gammacarboxylation of osteocalcin. Am J Clin Nutr. 2006;83(2):380-386. doi: https://doi.org/10.1093/ajcn/83.2.380Tsugawa N, Shiraki M, Suhara Y, et al. Vitamin K status of healthy Japanese women: age-related vitamin K requirement for gammacarboxylation of osteocalcin. Am J Clin Nutr. 2006;83(2):380-386. doi: https://doi.org/10.1093/ajcn/83.2.380Theuwissen E, Smit E, Vermeer C. The role of vitamin K in soft-tissue calcification. Adv Nutr. 2012;3(2):166-173. doi: https://doi.org/10.3945/an.111.001628Theuwissen E, Smit E, Vermeer C. The role of vitamin K in soft-tissue calcification. Adv Nutr. 2012;3(2):166-173. doi: https://doi.org/10.3945/an.111.001628Iwamoto J, Takeda T, Ichimura S. Treatment with vitamin D3 and/or vitamin K2 for postmenopausal osteoporosis. Keio J Med. 2003;52(3):147-150. doi: https://doi.org/10.2302/kjm.52.147Iwamoto J, Takeda T, Ichimura S. Treatment with vitamin D3 and/or vitamin K2 for postmenopausal osteoporosis. Keio J Med. 2003;52(3):147-150. doi: https://doi.org/10.2302/kjm.52.147Ushiroyama T, Ikeda A, Ueki M. Effect of continuous combined therapy with vitamin K(2) and vitamin D(3) on bone mineral density and coagulofibrinolysis function in postmenopausal women. Maturitas. 2002;41(3):211-221. doi: https://doi.org/10.1016/s0378-5122(01)00275-4Ushiroyama T, Ikeda A, Ueki M. Effect of continuous combined therapy with vitamin K(2) and vitamin D(3) on bone mineral density and coagulofibrinolysis function in postmenopausal women. Maturitas. 2002;41(3):211-221. doi: https://doi.org/10.1016/s0378-5122(01)00275-4Tanaka I, Oshima H. Vitamin K2 as a potential therapeutic agent for glucocorticoid -induced osteoporosis. Clinical calcium. 2007;17(11):1738-1744.Tanaka I, Oshima H. Vitamin K2 as a potential therapeutic agent for glucocorticoid -induced osteoporosis. Clinical calcium. 2007;17(11):1738-1744.Kanellakis S, Moschonis G, Tenta R, et al. Changes in parameters of bone metabolism in postmenopausal women following a 12-month intervention period using dairy products enriched with calcium, vitamin D, and phylloquinone (vitamin K(1)) or menaquinone-7 (vitamin K (2)): the Postmenopausal Health Study II. Calcif Tissue Int. 2012;90(4):251-262. doi: https://doi.org/10.1007/s00223-012-9571-zKanellakis S, Moschonis G, Tenta R, et al. Changes in parameters of bone metabolism in postmenopausal women following a 12-month intervention period using dairy products enriched with calcium, vitamin D, and phylloquinone (vitamin K(1)) or menaquinone-7 (vitamin K (2)): the Postmenopausal Health Study II. Calcif Tissue Int. 2012;90(4):251-262. doi: https://doi.org/10.1007/s00223-012-9571-zZhang Y, Liu Z, Duan L, et al. Effect of Low-Dose Vitamin K2 Supplementation on Bone Mineral Density in Middle-Aged and Elderly Chinese: A Randomized Controlled Study. Calcif Tissue Int. 2020;106(5):476-485. doi: https://doi.org/10.1007/s00223-020-00669-4Zhang Y, Liu Z, Duan L, et al. Effect of Low-Dose Vitamin K2 Supplementation on Bone Mineral Density in Middle-Aged and Elderly Chinese: A Randomized Controlled Study. Calcif Tissue Int. 2020;106(5):476-485. doi: https://doi.org/10.1007/s00223-020-00669-4Suzuki K, Tsuji S, Fukushima Y, et al. Clinical results of alendronate monotherapy and combined therapy with menatetrenone (VitK2) in postmenopausal RA patients. Mod Rheumatol. 2013;23(3):450-455. doi: https://doi.org/10.1007/s10165-012-0678-xSuzuki K, Tsuji S, Fukushima Y, et al. Clinical results of alendronate monotherapy and combined therapy with menatetrenone (VitK2) in postmenopausal RA patients. Mod Rheumatol. 2013;23(3):450-455. doi: https://doi.org/10.1007/s10165-012-0678-xTanaka S, Miyazaki T, Uemura Y, et al. Comparison of concurrent treatment with vitamin K2 and risedronate compared with treatment with risedronate alone in patients with osteoporosis: Japanese Osteoporosis Intervention Trial-03. J Bone Miner Metab. 2017;35(4):385-395. doi: https://doi.org/10.1007/s00774-016-0768-5Tanaka S, Miyazaki T, Uemura Y, et al. Comparison of concurrent treatment with vitamin K2 and risedronate compared with treatment with risedronate alone in patients with osteoporosis: Japanese Osteoporosis Intervention Trial-03. J Bone Miner Metab. 2017;35(4):385-395. doi: https://doi.org/10.1007/s00774-016-0768-5Jiang N, Xia W. Assessment of bone quality in patients with diabetes mellitus. Osteoporos Int. 2018;29(8):1721-1736. doi: https://doi.org/10.1007/s00198-018-4532-7Jiang N, Xia W. Assessment of bone quality in patients with diabetes mellitus. Osteoporos Int. 2018;29(8):1721-1736. doi: https://doi.org/10.1007/s00198-018-4532-7Shah VN, Carpenter RD, Ferguson VL, Schwartz AV. Bone health in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes. 2018;25(4):231-236. doi: https://doi.org/10.1097/MED.0000000000000421Shah VN, Carpenter RD, Ferguson VL, Schwartz AV. Bone health in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes. 2018;25(4):231-236. doi: https://doi.org/10.1097/MED.0000000000000421Hamilton EJ, Rakic V, Davis WA, et al. Prevalence and predictors of osteopenia and osteoporosis in adults with Type 1 diabetes. Diabet Med. 2009;26(1):45-52. doi: https://doi.org/10.1111/j.1464-5491.2008.02608.xHamilton EJ, Rakic V, Davis WA, et al. Prevalence and predictors of osteopenia and osteoporosis in adults with Type 1 diabetes. Diabet Med. 2009;26(1):45-52. doi: https://doi.org/10.1111/j.1464-5491.2008.02608.xMaggio AB, Ferrari S, Kraenzlin M, et al. Decreased bone turnover in children and adolescents with well controlled type 1 diabetes. J Pediatr Endocrinol Metab. 2010;23(7):697-707. doi: https://doi.org/10.1515/jpem.2010.23.7.697Maggio AB, Ferrari S, Kraenzlin M, et al. Decreased bone turnover in children and adolescents with well controlled type 1 diabetes. J Pediatr Endocrinol Metab. 2010;23(7):697-707. doi: https://doi.org/10.1515/jpem.2010.23.7.697Bonds DE, Larson JC, Schwartz AV, et al. Risk of fracture in women with type 2 diabetes: the Women’s Health Initiative Observational Study. J Clin Endocrinol Metab. 2006;91(9):3404-3410. doi: https://doi.org/10.1210/jc.2006-0614Bonds DE, Larson JC, Schwartz AV, et al. Risk of fracture in women with type 2 diabetes: the Women’s Health Initiative Observational Study. J Clin Endocrinol Metab. 2006;91(9):3404-3410. doi: https://doi.org/10.1210/jc.2006-0614Sundararaghavan V, Mazur MM, Evans B, Liu J, Ebraheim NA. Diabetes and bone health: latest evidence and clinical implications. Ther Adv Musculoskelet Dis. 2017;9(3):67-74. doi: https://doi.org/10.1177/1759720X16687480Sundararaghavan V, Mazur MM, Evans B, Liu J, Ebraheim NA. Diabetes and bone health: latest evidence and clinical implications. Ther Adv Musculoskelet Dis. 2017;9(3):67-74. doi: https://doi.org/10.1177/1759720X16687480Zhukouskaya VV, Eller-Vainicher C, Gaudio A, et al. The utility of lumbar spine trabecular bone score and femoral neck bone mineral density for identifying asymptomatic vertebral fractures in well-compensated type 2 diabetic patients [published correction appears in Osteoporos Int. 2016;27(1):421. Ellen-Vainicher C [Corrected to Eller-Vainicher C]]. Osteoporos Int. 2016;27(1):49-56. doi: https://doi.org/10.1007/s00198-015-3212-0Zhukouskaya VV, Eller-Vainicher C, Gaudio A, et al. The utility of lumbar spine trabecular bone score and femoral neck bone mineral density for identifying asymptomatic vertebral fractures in well-compensated type 2 diabetic patients [published correction appears in Osteoporos Int. 2016;27(1):421. Ellen-Vainicher C [Corrected to Eller-Vainicher C]]. Osteoporos Int. 2016;27(1):49-56. doi: https://doi.org/10.1007/s00198-015-3212-0Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes — a meta-analysis. Osteoporos Int. 2007;18(4):427-444. doi: https://doi.org/10.1007/s00198-006-0253-4Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes — a meta-analysis. Osteoporos Int. 2007;18(4):427-444. doi: https://doi.org/10.1007/s00198-006-0253-4Neumann T, Lodes S, Kästner B, et al. Trabecular bone score in type 1 diabetes--a cross-sectional study. Osteoporos Int. 2016;27(1):127-133. doi: https://doi.org/10.1007/s00198-015-3222-yNeumann T, Lodes S, Kästner B, et al. Trabecular bone score in type 1 diabetes--a cross-sectional study. Osteoporos Int. 2016;27(1):127-133. doi: https://doi.org/10.1007/s00198-015-3222-yKim JH, Choi HJ, Ku EJ, et al. Trabecular bone score as an indicator for skeletal deterioration in diabetes. J Clin Endocrinol Metab. 2015;100(2):475-482. doi: https://doi.org/10.1210/jc.2014-2047Kim JH, Choi HJ, Ku EJ, et al. Trabecular bone score as an indicator for skeletal deterioration in diabetes. J Clin Endocrinol Metab. 2015;100(2):475-482. doi: https://doi.org/10.1210/jc.2014-2047McCloskey EV, Odén A, Harvey NC, et al. A Meta-Analysis of Trabecular Bone Score in Fracture Risk Prediction and Its Relationship to FRAX. J Bone Miner Res. 2016;31(5):940-948. doi: https://doi.org/10.1002/jbmr.2734McCloskey EV, Odén A, Harvey NC, et al. A Meta-Analysis of Trabecular Bone Score in Fracture Risk Prediction and Its Relationship to FRAX. J Bone Miner Res. 2016;31(5):940-948. doi: https://doi.org/10.1002/jbmr.2734Napoli N, Chandran M, Pierroz DD, et al. Mechanisms of diabetes mellitus-induced bone fragility. Nat Rev Endocrinol. 2017;13(4):208-219. doi: https://doi.org/10.1038/nrendo.2016.153Napoli N, Chandran M, Pierroz DD, et al. Mechanisms of diabetes mellitus-induced bone fragility. Nat Rev Endocrinol. 2017;13(4):208-219. doi: https://doi.org/10.1038/nrendo.2016.153Федорова О.С., Гурьева И.В., Cтроков И.А. Влияние дистальной полинейропатии на нарушение равновесия у больных сахарным диабетом // Медицинский Совет. — 2013. — №12. — С. 118-119.Fedorova ОS, Gurieva IV, Strokov IA. The effect of distal polyneuropathy on balance disorder in patients with diabetes. Medical Council. 2013;(12):118-119. (In Russ.). doi: https://doi.org/10.21518/2079-701X-2013-12-118-119Kalaitzoglou E, Popescu I, Bunn RC, et al. Effects of Type 1 Diabetes on Osteoblasts, Osteocytes, and Osteoclasts. Curr Osteoporos Rep. 2016;14(6):310-319. doi: https://doi.org/10.1007/s11914-016-0329-9Kalaitzoglou E, Popescu I, Bunn RC, et al. Effects of Type 1 Diabetes on Osteoblasts, Osteocytes, and Osteoclasts. Curr Osteoporos Rep. 2016;14(6):310-319. doi: https://doi.org/10.1007/s11914-016-0329-9Kierdorf K, Fritz G. RAGE regulation and signaling in inflammation and beyond. J Leukoc Biol. 2013;94(1):55-68. doi: https://doi.org/10.1189/jlb.1012519Kierdorf K, Fritz G. RAGE regulation and signaling in inflammation and beyond. J Leukoc Biol. 2013;94(1):55-68. doi: https://doi.org/10.1189/jlb.1012519Aikawa E, Fujita R, Asai M, et al. Receptor for Advanced Glycation End Products-Mediated Signaling Impairs the Maintenance of Bone Marrow Mesenchymal Stromal Cells in Diabetic Model Mice. Stem Cells Dev. 2016;25(22):1721-1732. doi: https://doi.org/10.1089/scd.2016.0067Aikawa E, Fujita R, Asai M, et al. Receptor for Advanced Glycation End Products-Mediated Signaling Impairs the Maintenance of Bone Marrow Mesenchymal Stromal Cells in Diabetic Model Mice. Stem Cells Dev. 2016;25(22):1721-1732. doi: https://doi.org/10.1089/scd.2016.0067Lewiecki EM. Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases. Ther Adv Musculoskelet Dis. 2014;6(2):48-57. doi: https://doi.org/10.1177/1759720X13510479Lewiecki EM. Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases. Ther Adv Musculoskelet Dis. 2014;6(2):48-57. doi: https://doi.org/10.1177/1759720X13510479Wędrychowicz A, Sztefko K, Starzyk JB. Sclerostin and its significance for children and adolescents with type 1 diabetes mellitus (T1D). Bone. 2019;120:387-392. doi: https://doi.org/10.1016/j.bone.2018.08.007Wędrychowicz A, Sztefko K, Starzyk JB. Sclerostin and its significance for children and adolescents with type 1 diabetes mellitus (T1D). Bone. 2019;120:387-392. doi: https://doi.org/10.1016/j.bone.2018.08.007Yamamoto M, Yamauchi M, Sugimoto T. Elevated sclerostin levels are associated with vertebral fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2013;98(10):4030-4037. doi: https://doi.org/10.1210/jc.2013-2143Yamamoto M, Yamauchi M, Sugimoto T. Elevated sclerostin levels are associated with vertebral fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2013;98(10):4030-4037. doi: https://doi.org/10.1210/jc.2013-2143Rubin MR, Patsch JM. Assessment of bone turnover and bone quality in type 2 diabetic bone disease: current concepts and future directions. Bone Res. 2016;4(1):16001. doi: https://doi.org/10.1038/boneres.2016.1Rubin MR, Patsch JM. Assessment of bone turnover and bone quality in type 2 diabetic bone disease: current concepts and future directions. Bone Res. 2016;4(1):16001. doi: https://doi.org/10.1038/boneres.2016.1Starup-Linde J, Eriksen SA, Lykkeboe S, et al. Biochemical markers of bone turnover in diabetes patients--a metaanalysis, and a methodological study on the effects of glucose on bone markers. Osteoporos Int. 2014;25(6):1697-1708. doi: https://doi.org/10.1007/s00198-014-2676-7Starup-Linde J, Eriksen SA, Lykkeboe S, et al. Biochemical markers of bone turnover in diabetes patients--a metaanalysis, and a methodological study on the effects of glucose on bone markers. Osteoporos Int. 2014;25(6):1697-1708. doi: https://doi.org/10.1007/s00198-014-2676-7Bone HG, Lindsay R, McClung MR, et al. Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebocontrolled study. J Clin Endocrinol Metab. 2013;98(12):4691-4701. doi: https://doi.org/10.1210/jc.2012-4096Bone HG, Lindsay R, McClung MR, et al. Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebocontrolled study. J Clin Endocrinol Metab. 2013;98(12):4691-4701. doi: https://doi.org/10.1210/jc.2012-4096Watts NB, Bilezikian JP, Usiskin K, et al. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 2016;101(1):157-166. doi: https://doi.org/10.1210/jc.2015-3167Watts NB, Bilezikian JP, Usiskin K, et al. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 2016;101(1):157-166. doi: https://doi.org/10.1210/jc.2015-3167Tang HL, Li DD, Zhang JJ, et al. Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2016;18(12):1199-1206. doi: https://doi.org/10.1111/dom.12742Tang HL, Li DD, Zhang JJ, et al. Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2016;18(12):1199-1206. doi: https://doi.org/10.1111/dom.12742Лебедев Д.А., Андреева А.Т., Кокина М.А., и др. Влияние терапии ингибитором натрий-глюкозного ко-транспортера 2 типа на фосфорно-кальциевый обмен у пациентов сахарным диабетом 2 типа // Остеопороз и остеопатии. — 2020. — Т. 23. — №2. — С. 84.Lebedev DA, Andreeva AT, Kokina MA, et al. The influence of treatment with the sodium-glucose co-transporter type 2 inhibitors for phosphorus-calcium exchange inpatients with type 2 diabetes. Osteoporosis and Bone Diseases. 2020;23(2):84. (In Russ.).Li Y, Chen JP, Duan L, Li S. Effect of vitamin K2 on type 2 diabetes mellitus: A review. Diabetes Res Clin Pract. 2018;136:39-51. doi: https://doi.org/10.1016/j.diabres.2017.11.020Li Y, Chen JP, Duan L, Li S. Effect of vitamin K2 on type 2 diabetes mellitus: A review. Diabetes Res Clin Pract. 2018;136:39-51. doi: https://doi.org/10.1016/j.diabres.2017.11.020Yasuda S, Wada S. Diabetic osteopahty and vitamin K. Clin Calcium. 2006;16(8):1351-57. doi: https://doi.org/CliCa060813511357Yasuda S, Wada S. Diabetic osteopahty and vitamin K. Clin Calcium. 2006;16(8):1351-57. doi: https://doi.org/CliCa060813511357Poon CC, Li RW, Seto SW, et al. In vitro vitamin K(2) and 1α,25- dihydroxyvitamin D(3) combination enhances osteoblasts anabolism of diabetic mice. Eur J Pharmacol. 2015;767:30-40. doi: https://doi.org/10.1016/j.ejphar.2015.09.048Poon CC, Li RW, Seto SW, et al. In vitro vitamin K(2) and 1α,25- dihydroxyvitamin D(3) combination enhances osteoblasts anabolism of diabetic mice. Eur J Pharmacol. 2015;767:30-40. doi: https://doi.org/10.1016/j.ejphar.2015.09.048Iwamoto J, Seki A, Sato Y, et al. Vitamin K2 prevents hyperglycemia and cancellous osteopenia in rats with streptozotocininduced type 1 diabetes. Calcif Tissue Int. 2011;88(2):162-168. doi: https://doi.org/10.1007/s00223-010-9441-5Iwamoto J, Seki A, Sato Y, et al. Vitamin K2 prevents hyperglycemia and cancellous osteopenia in rats with streptozotocininduced type 1 diabetes. Calcif Tissue Int. 2011;88(2):162-168. doi: https://doi.org/10.1007/s00223-010-9441-5Horiuchi T, Kazama H, Araki A, et al. Impaired gamma carboxylation of osteocalcin in elderly women with type II diabetes mellitus: relationship between increase in undercarboxylated osteocalcin levels and low bone mineral density. J Bone Miner Metab. 2004;22(3):236-240. doi: https://doi.org/10.1007/s00774-003-0473-zHoriuchi T, Kazama H, Araki A, et al. Impaired gamma carboxylation of osteocalcin in elderly women with type II diabetes mellitus: relationship between increase in undercarboxylated osteocalcin levels and low bone mineral density. J Bone Miner Metab. 2004;22(3):236-240. doi: https://doi.org/10.1007/s00774-003-0473-zAguayo-Ruiz JI, García-Cobián TA, Pascoe-González S, et al. Effect of supplementation with vitamins D3 and K2 on undercarboxylated osteocalcin and insulin serum levels in patients with type 2 diabetes mellitus: a randomized, double-blind, clinical trial. Diabetol Metab Syndr. 2020;12:73. doi: https://doi.org/10.1186/s13098-020-00580-wAguayo-Ruiz JI, García-Cobián TA, Pascoe-González S, et al. Effect of supplementation with vitamins D3 and K2 on undercarboxylated osteocalcin and insulin serum levels in patients with type 2 diabetes mellitus: a randomized, double-blind, clinical trial. Diabetol Metab Syndr. 2020;12:73. doi: https://doi.org/10.1186/s13098-020-00580-wBartstra JW, Draaisma F, Zwakenberg SR, et al. Six months vitamin K treatment does not affect systemic arterial calcification or bone mineral density in diabetes mellitus 2. Eur J Nutr. 2021;60(3):1691-1699. doi: https://doi.org/10.1007/s00394-020-02412-zBartstra JW, Draaisma F, Zwakenberg SR, et al. Six months vitamin K treatment does not affect systemic arterial calcification or bone mineral density in diabetes mellitus 2. Eur J Nutr. 2021;60(3):1691-1699. doi: https://doi.org/10.1007/s00394-020-02412-z

The authors declare that there are no conflicts of interest present.